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hich Measures of
besity Best Predict
ardiovascular Risk?*
heldon E. Litwin, MD, FACC
alt Lake City, Utah
“The possible relationship between obesity and cardiovascular
disease has been the subject of great controversy.” (1)
n the 24 years since this statement was written, the
ontentiousness over the issue has evolved somewhat, but
as not abated. Today, there is general acceptance that
besity is a risk factor for cardiovascular disease (CVD).
owever, we now have difficulty in reaching a consensus on
he definition of obesity or on which specific aspects of
besity contribute to CVD. The major disagreement centers
n the topic of whether the total amount or the distribution
f adipose tissue confers the greater risk of developing
VD. One paradigm holds that generalized obesity, usually
ssessed by the body mass index (BMI) expressed in kg/m2,
dequately predicts the development of CVD or CVD-
ssociated death (2–12). The other school is entrenched in
he belief that central or abdominal obesity is the key
bnormality leading to cardiovascular pathology (13–16).
ccording to the latter theory, visceral fat, via a variety of
echanisms, is proatherogenic, but subcutaneous and/or
eripheral fat is not (17–25). Proponents of the central
besity hypothesis correctly point out that BMI misclassifies
ome people as being normal weight or obese (26). The
xtent to which such misclassification occurs in large pop-
lations is unclear because waist circumference and BMI
orrelate closely (26,27).
See page 605
Determining the best method for quantifying adiposity is
mportant because this may: 1) define higher- and lower-
isk subgroups of patients that require different levels of
reatment intensity (i.e., deciding when to aim for lower target
ow-density lipoprotein cholesterol levels) (28); and 2) reveal
nsights into the mechanisms by which obesity is linked to
ardiovascular maladies.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thet
merican College of Cardiology.
From the University of Utah School of Medicine, Salt Lake City, Utah.The World Health Organization has defined overweight
nd class I to III obesity based on BMI. This metric is very
asy to obtain, reproducible, unambiguous, and widely
ccepted and understood. Despite the relative crudeness of
he measure, in population studies including almost 3.5
illion people, increased BMI has consistently been shown
o predict total and cardiovascular mortality (2–12). The
elative risk of cardiovascular mortality in the highest BMI
roups has been reported to be 2 to 4 times that of the
ormal weight group in nearly all of the largest studies. The
revalence of overweight and obesity as defined by BMI is
apidly increasing, particularly in children and adolescents
29). At the same time, we are seeing an increase in the
everity of coronary disease in younger people (30). This has
ccurred despite increased use of evidence-based treatments
or hypertension and hyperlipidemia (31). Even more om-
nous, with the increasing prevalence of obesity, there
ppears to be a reversal of the 2-decade-long decline in
eath rates from CVD (32).
Abdominal obesity is a central component of the meta-
olic syndrome and is thought to play a specific role in
nsulin resistance and dyslipidemia (21). Given this, it is not
urprising that larger waist circumferences may be associ-
ted with a higher risk of developing CVD or cardiovascular
ortality. Interestingly, larger hip circumferences, suggest-
ng peripheral fat deposition, have been associated with less
evere CVD risk factors or a lower risk of incident CVD
33–35). Because of the opposing effects of waist and hip
ircumferences, the waist-to-hip ratio has become a popular
ethod of assessing atherogenic risk. Indeed, in a number
f studies the waist-to-hip ratio performed better than waist
ircumferences in predicting CVD (1,36–40). The adher-
nts of the visceral fat theory generally advocate obtaining
easures of central obesity such as waist circumference or a
irect measure of visceral fat obtained with computed
omography or magnetic resonance imaging. These mea-
ures, though appealing, have not been validated as exten-
ively as BMI. In addition, there is no clear consensus on
ow (or where) to measure these parameters or on defining
he optimal cutoff values for normal and abnormal. The
ebate over how to best define obesity is complicated by
bservations suggesting that BMI, waist circumference, or
aist-to-hip ratio may each perform better in predicting
ardiovascular risk in specific populations, depending on
ender, age, and ethnicity. For example, in older patients,
MI is less robust at predicting an increased relative risk of
VD-related mortality even though higher BMI is strongly
elated to increased absolute mortality in the elderly (11,41).
lthough it has not been examined rigorously, there is some
uggestion in the existing literature that BMI is a less robust
redictor of CVD than waist circumference in women but
ot in men (9,15). The “android” pattern of obesity (central
besity) is less common in women, and thus, increased waist
ircumference might confer a higher relative risk in women
han in men.
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August 19, 2008:616–19 Editorial CommentTwo recent studies readdress the topic and reach different
onclusions. Zhang et al. (26) calculated total and cause-
pecific mortality in a subset of patients from the Nurse’s
ealth Study (42). Their analysis included 44,636 partici-
ants who reported waist circumference on the 1986 ques-
ionnaire (from the initial cohort of 115,195 subjects en-
olled in 1976). They found correlation coefficients of 0.81
nd 0.96 between waist circumference and BMI or waist/
eight, respectively. Their main conclusion was that mea-
ures of abdominal obesity were strongly and positively
ssociated with all-cause and cardiovascular mortality inde-
endently of BMI. The relative risk of age-adjusted CVD
ortality was 2.02 for the highest versus the lowest quintiles
f waist circumference. Furthermore, they found that ele-
ated waist circumference was associated with increased
ardiovascular mortality even in normal weight women.
nterestingly, an earlier report that included data from the
ntire cohort enrolled in the Nurse’s Health Study found
hat women with a BMI 32 kg/m2 and who had never
moked had a 4.1-fold increase in the relative risk of death
rom CVD (7). The earlier report indicated that lean
omen did not have excess mortality.
In this issue of the Journal, Gelber et al. (27) analyze
xisting data from 2 large clinical trials—the Physician’s
ealth Study (43) and the Women’s Health Study (44).
hese investigators conclude that BMI is clinically equiva-
ent to waist circumference in predicting major CVD events
r death. The results of the current study may not resolve
he controversy, but do provide some practical suggestions
bout the most useful way to define obesity. The large size
f the cohorts in this study (more than 49,000 participants),
he inclusion of both men and women, the relatively long
uration of follow-up (9 years for the Physician’s Health
tudy and 6 years for the Women’s Health Study), the
ignificant number of adjudicated hard end points (1,505
ases of first nonfatal myocardial infarction, nonfatal isch-
mic stroke, or cardiovascular death), and the adjustment for
ultiple relevant covariates strengthen the conclusions of
his study. The main findings were that all measures of
diposity (BMI, waist circumference, waist-to-hip ratio,
nd waist-to-height ratio [WHtR]) correlated with each
ther (r values of 0.8) and with incident CVD. Although
HtR had the strongest gradient in the association with
ncident CVD (e.g., a greater relative risk for each incre-
ent of the various anthropometric variables), the investi-
ators concluded that “differences between BMI and WHtR
n association with CVD.. . [are] small and likely not
linically consequential.” Furthermore, they assert, “BMI
ay remain the most clinically practical measure of adipos-
ty” (27).
I find these conclusions to be refreshing. Clinical practi-
ality is frequently overshadowed by statistical significance.
any readers of this journal are all too familiar with the
ealities of struggling to move patients efficiently through
ur offices while still documenting all necessary bullet
oints, examining the patient, reviewing their test results, and spending time counseling them and answering ques-
ions. Do we really need multiple measures of body size or
eometry to determine if our patient is overweight or obese?
ill our patients tolerate having their waist and hip
ircumferences measured? The “eyeball test” is probably a
easonable method for assessing adiposity in most instances.
ecause quantitation of adiposity allows a more detailed risk
ssessment and allows comparison of changes over time, an
nambiguous, simple parameter to support our visual and
linical assessment will be useful. The data shown by Gelber
t al. (27) argue that BMI should be that single measure.
ure, there are patients in whom the BMI will give an
naccurate assessment of adiposity. For example, those with
arge body frames and heavy muscle mass may be incorrectly
lassified as obese, but at the other end of the spectrum,
hose with muscle wasting, yet still replete with adipose
issue could be classified as lean (particularly elderly sub-
ects) (45). However, these are relatively small subsets of the
atients we see in today’s medical practices. Do we really
eed to measure waist and hip circumferences (with their
nherent inaccuracies based on location of the measure-
ent), or worse yet, perform routine abdominal computed
omography scans to identify the well-muscled football
layer or the elderly patient with little muscle mass but
bdominal obesity? I think not.
The medical profession suffers in the eyes of the public
ecause we bombard them with conflicting data and incon-
istent conclusions. They grow confused and disillusioned
ith our controversies. Who among us has not been asked
y our own friends and family whether they are better off
ating a diet low in total fat, low in saturated fat, low in
holesterol, or low in carbohydrates? Can you give them a
ogent answer? Let us not fall into the trap of uncertainty
hen it comes to discussing the topic of obesity. Given the
mportance of obesity as a public health issue, it behooves us
o keep sight of the big picture. The obesity epidemic will
ikely bring an end to the steadily progressive increases in
verall life expectancy that we have witnessed in our
ifetimes (46). With no end in sight to the growing
pidemic, obesity arguably poses the greatest challenge of
ny medical condition to worldwide health in the foresee-
ble future.
As medical professionals and scientists, let us speak with a
nited, unequivocal voice when we talk to our patients about
besity. We should not vacillate about how we measure or
efine obesity. There is no “good” fat—the fat cell is the
nemy. This concept must be clear and simple when we
ddress patients, friends, family, and the public. For the
urposes of research, it is important to understand the patho-
hysiology of obesity-related CVD. To this end, teasing out
he different subtypes, distributions, or patterns of obesity and
heir relation to CVD is a highly worthy goal. However, for the
ake of our patients, we must stay on the message. All obesity
s potentially deleterious. Regardless of how we define obesity,
t is putting today’s children at risk. The BMI is the simplest
nd most widely accepted measure of obesity. Few other
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Editorial Comment August 19, 2008:616–19ndexes have been so extensively studied and validated. As a
rofession, we serve our patients and our communities best by
ingularly adopting this metric.
eprint request and correspondence: Dr. Sheldon E. Litwin,
niversity of Utah School of Medicine, 30 N. 1900 E., 4A100 SOM,
alt Lake City, Utah 84132. E-mail: sheldon.litwin@hsc.
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